Grupo Aval Q2 2026 revenue beats forecast as shares climb
Latin America's largest bank by assets reports higher-than-expected revenue for Q2 2026, lifting shares amid investor optimism.

Grupo Aval, Colombia's largest financial group by assets, reported second-quarter 2026 revenue that exceeded market forecasts, driving a rise in its shares on Tuesday.
The company, which operates through subsidiaries including Banco de Bogotá and Banco de Occidente, did not disclose specific revenue figures in the preliminary update. Analysts had projected revenue of approximately $1.85 billion for the quarter, according to consensus estimates compiled by Reuters. The outperformance follows a period of cautious investor sentiment amid regional economic uncertainty.
Shares of Grupo Aval closed 3.2% higher at 18,200 Colombian pesos, extending gains from the prior session. The stock has gained about 8% over the past month, outperforming the broader Colombian equity benchmark, the COLCAP index, which is up 4.5% over the same period.
Analysts attributed the revenue beat to stronger-than-expected loan growth and improved net interest margins across its banking operations. The company’s net interest income rose 5.1% year-over-year, supported by higher lending volumes and a steadier interest rate environment in Colombia.
Grupo Aval’s management is scheduled to hold an earnings call on Thursday to provide further details on the quarter’s performance, including profitability metrics and asset quality trends. Investors will focus on guidance for the second half of 2026, particularly in light of recent volatility in Latin American financial markets.
The bank’s outperformance contrasts with broader regional challenges, including elevated inflation and currency volatility in key markets. However, Grupo Aval’s diversified revenue streams across retail, corporate, and SME lending have positioned it relatively well against peers.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
